Expand XRTX Menu
XRTX MENU

XRTX Latest Press Releases

-- September 18, 2026 --

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO , Targeting USD$700M+ U.S. Gout Market Opportunity Globe Newswire 8:05 AM

-- September 10, 2026 --

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO Globe Newswire 4:05 PM

-- September 8, 2026 --

XORTX Re-Engages Investor Relations Program Globe Newswire 6:15 PM

-- August 28, 2026 --

XORTX Announces Termination and Postponement of Investor Relations Program Globe Newswire 7:00 AM

-- July 31, 2026 --

XORTX Announces Director Resignation Globe Newswire 5:00 PM

-- July 29, 2026 --

XORTX Appoints New Director Globe Newswire 7:00 AM

-- June 15, 2026 --

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO Globe Newswire 7:00 AM

-- June 12, 2026 --

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange Globe Newswire 5:00 PM

-- May 19, 2026 --

XORTX Announces Closing of US$5 Million Public Offering Globe Newswire 7:00 AM

-- May 18, 2026 --

E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering Globe Newswire 11:20 AM

-- May 14, 2026 --

XORTX Announces US$5 Million Public Offering Globe Newswire 7:00 AM

-- April 21, 2026 --

XORTX Meets Nasdaq Continued Listing Requirements Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes